HEIDELBERG, Allemagne & CAMBRIDGE, Massachussets–(BUSINESS WIRE)–Novaliq, une entreprise biopharmaceutique spécialisée dans les thérapies oculaires de premier ordre et uniques basées sur la technologie sans eau EyeSol® , annonce que le Comité des méd…
Author: Business Wire
Novaliq erhält positives CHMP-Gutachten für Vevizye® bei Trockenem-Auge-Syndrom
HEIDELBERG, Deutschland & CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Novaliq, ein biopharmazeutisches Unternehmen, das sich auf erste und beste Augentherapeutika konzentriert, die auf der einzigartigen wasserfreien EyeSol®-Technologie basieren, gibt be…
NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Option
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants, Series F-1 w…
Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease
HEIDELBERG, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)– #CHMP–Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announces that the European Medicines Agen…
Virginia State Parks Becomes First in the Nation to Install EnChroma-adapted Viewfinders for Colorblind Guests at Every Park
RICHMOND, Va. & BERKELEY, Calif.–(BUSINESS WIRE)– #enchroma–Virginia State Parks becomes first in the nation to install EnChroma-adapted viewfinders for colorblind guests at every park to improve accessibility
NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”), today announced the pricing of its underwritten public offering of 3,200,380 shares of common stock (or pre-funded warrants in lieu th…
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August 7, 2024, after…
National Vision Holdings, Inc. Announces Second Quarter 2024 Earnings Release and Conference Call
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024 and will host a conference call a…
National Vision Announces Optometry Students Selected to Win $7,000 in Scholarships
DULUTH, Ga.–(BUSINESS WIRE)–National Vision, Inc., one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, announced the winners of its 2024 National Optometric Student Association (NOSA) scholarships. Throug…
CenterWell Announces Plans to Open 23 Senior Primary Care Centers at Walmart Locations in Florida, Georgia, Missouri and Texas
LOUISVILLE, Ky.–(BUSINESS WIRE)–CenterWell, the health care services business of Humana Inc. (NYSE: HUM), today announced plans to lease clinical space and open senior-focused primary care centers at 23 Walmart Supercenter retail stores in Florida, G…
BCF, BREF and TBG Companies Seek Global Financial Support to Establish 1000s of Best Cure Pro Health and Medical Centers
WASHINGTON–(BUSINESS WIRE)–Dr. Krishnan Suthanthiran is the Founder and President of the Best Cure Foundation (BCF), a non-profit 501(c)(3) corporation established in Springfield, Virginia, USA, in 2007. He also established the Brachytherapy Research…
Osheru Secures $4.7 Million Seed Funding to Advance Revolutionary Ziplyft Device for Blepharoplasty Surgery
BEND, Ore.–(BUSINESS WIRE)–Osheru, a medical device company specializing in innovative solutions for skin surgery led by Drs. Knute and Patricia Buehler, announced today the successful completion of a $4.7 million funding round to accelerate the deve…
GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics publie sa position de trésorerie au 30 juin 2024, et fait le point sur ses activités
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN: FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurodé…
Samsara Vision Announces First SING IMT® (Smaller-Incision New-Generation Implantable Miniature Telescope) Patient in China and Accelerating Global Rollout
FAR HILLS, N.J.–(BUSINESS WIRE)– #AMD–Samsara Vision Announces 1st SING IMT® (Smaller-Incision New-Generation Implantable Miniature Telescope) Patient in China & Update on Global Rollout
Spryte Medical Receives Breakthrough Device Designation from FDA for Revolutionary neuro Optical Coherence Tomography (nOCT) Technology
BEDFORD, Mass.–(BUSINESS WIRE)–Spryte Medical, a pioneering company in advanced medical imaging technologies, proudly announces that its neuro Optical Coherence Tomography (nOCT) technology has been granted Breakthrough Device Designation by the U.S….
Ora Announces Strategic Investment from The Vistria Group to Propel Global Growth, Enhance Customer Experience in Ophthalmic Research
BOSTON & CHICAGO–(BUSINESS WIRE)– #Innovation–Leading Ophthalmic CRO Ora announces recapitalization by The Vistria Group, New CEO Paul Colvin
Median Technologies Reports Record iCRO Backlog, eyonis™ LCS On-Track for Standalone Pivotal Study Readout in August
SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Median Technologies Reports Record iCRO Backlog, eyonis™ LCS On-Track for Standalone Pivotal Study Readout in August
New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (ranibizumab injection) 100 mg/mL for th…
Warby Parker to Announce Second Quarter 2024 Financial Results on August 8, 2024
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the second quarter ended June 30, 2024 will be released before mar…